Commonly used diabetes and cardiovascular medications and cancer recurrence and cancer-specific mortality: a review of the literature

Wu, Jiao; Boudreau, Denise M.; Park, Yikyung; Simonds, Naoko I.; Freedman, Andrew

doi:10.1517/14740338.2014.926887

Cited by 28 publications

(13 citation statements)

References 154 publications

(261 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Notably, in the United Kingdom Prospective Diabetes Study (UKPDS), metformin use, compared with other antidiabetic drugs, decreased the risk of cardiovascular disease (Group, 1998), cancer incidence and overall mortality (Wu et al ., 2014), and possibly cognitive decline (Ng et al ., 2014). Safety has been established and the pro-longevity effects noted would argue for testing the use of metformin in humans.…”

Section: Activators Of the Ampk Pathwaymentioning

confidence: 99%

Interventions to Slow Aging in Humans: Are We Ready?

et al. 2015

View full text Add to dashboard Cite

The workshop entitled ‘Interventions to Slow Aging in Humans: Are We Ready?’ was held in Erice, Italy, on October 8–13, 2013, to bring together leading experts in the biology and genetics of aging and obtain a consensus related to the discovery and development of safe interventions to slow aging and increase healthy lifespan in humans. There was consensus that there is sufficient evidence that aging interventions will delay and prevent disease onset for many chronic conditions of adult and old age. Essential pathways have been identified, and behavioral, dietary, and pharmacologic approaches have emerged. Although many gene targets and drugs were discussed and there was not complete consensus about all interventions, the participants selected a subset of the most promising strategies that could be tested in humans for their effects on healthspan. These were: (i) dietary interventions mimicking chronic dietary restriction (periodic fasting mimicking diets, protein restriction, etc.); (ii) drugs that inhibit the growth hormone/IGF-I axis; (iii) drugs that inhibit the mTOR–S6K pathway; or (iv) drugs that activate AMPK or specific sirtuins. These choices were based in part on consistent evidence for the pro-longevity effects and ability of these interventions to prevent or delay multiple age-related diseases and improve healthspan in simple model organisms and rodents and their potential to be safe and effective in extending human healthspan. The authors of this manuscript were speakers and discussants invited to the workshop. The following summary highlights the major points addressed and the conclusions of the meeting.

show abstract

Section: Activators Of the Ampk Pathwaymentioning

confidence: 99%

Interventions to Slow Aging in Humans: Are We Ready?

et al. 2015

View full text Add to dashboard Cite

show abstract

“… 55 Additionally, there are also many studies that focus on whether antiaging effects of metformin can be demonstrated in patients with T2DM. In the United Kingdom Prospective Diabetes Study (UKPDS), the use of metformin decreased the risk of cardiovascular disease, 56 cancer incidence and overall mortality, 57 compared with other antidiabetic drugs. Furthermore, a large retrospective observational study including over 180,000 subjects showed that patients with T2DM initiated with metformin monotherapy had longer survival than did matched, non-diabetic controls; however, in this study they did not investigate for a dose-response association.…”

Section: Antiaging Effect Of Metforminmentioning

confidence: 99%

Metformin: a review of its potential indications

Wang

Xiao

et al. 2017

DDDT

243

174

View full text Add to dashboard Cite

Metformin is the most commonly prescribed drug for type 2 diabetes mellitus. In recent years, in addition to glucose lowering, several studies have presented evidence suggesting some potential role for metformin, such as antitumor effect, antiaging effect, cardiovascular protective effect, neuroprotective effect or an optional treatment for polycystic ovary syndrome. This paper will critically review the role of metformin to provide reference for doctors and researchers.

show abstract

“…Over the last decade, epidemiologic studies have indicated that use of β-blockers may have beneficial effects on cancer progression, metastasis, and mortality ( 15 – 24 ). β-blockers form a group of commonly prescribed drugs used as treatment for hypertension, cardiac heart failure, and arrhythmias, as well as for migraine prophylaxis.…”

Section: Introductionmentioning

confidence: 99%

Î²-Adrenergic Receptor Signaling in Prostate Cancer

et al. 2015

View full text Add to dashboard Cite

Enhanced sympathetic signaling, often associated with obesity and chronic stress, is increasingly acknowledged as a contributor to cancer aggressiveness. In prostate cancer, intact sympathetic nerves are critical for tumor formation, and sympathectomy induces apoptosis and blocks tumor growth. Perineural invasion, involving enrichment of intra-prostatic nerves, is frequently observed in prostate cancer and is associated with poor prognosis. β2-adrenergic receptor (ADRB2), the most abundant receptor for sympathetic signals in prostate luminal cells, has been shown to regulate trans-differentiation of cancer cells to neuroendocrine-like cells and to affect apoptosis, angiogenesis, epithelial–mesenchymal transition, migration, and metastasis. Epidemiologic studies have shown that use of β-blockers, inhibiting β-adrenergic receptor activity, is associated with reduced prostate cancer-specific mortality. In this review, we aim to present an overview on how β-adrenergic receptor and its downstream signaling cascade influence the development of aggressive prostate cancer, primarily through regulating neuroendocrine differentiation.

show abstract

Commonly used diabetes and cardiovascular medications and cancer recurrence and cancer-specific mortality: a review of the literature

Cited by 28 publications

References 154 publications

Interventions to Slow Aging in Humans: Are We Ready?

Interventions to Slow Aging in Humans: Are We Ready?

Metformin: a review of its potential indications

Î²-Adrenergic Receptor Signaling in Prostate Cancer

Contact Info

Product

Resources

About